Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Minor snRNA gene delivery improves the loss of proprioceptive synapses on SMA motor neurons
Erkan Y. Osman, … , Livio Pellizzoni, Christian L. Lorson
Erkan Y. Osman, … , Livio Pellizzoni, Christian L. Lorson
Published June 9, 2020
Citation Information: JCI Insight. 2020;5(12):e130574. https://doi.org/10.1172/jci.insight.130574.
View: Text | PDF
Research Article Neuroscience

Minor snRNA gene delivery improves the loss of proprioceptive synapses on SMA motor neurons

  • Text
  • PDF
Abstract

Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder caused by reduced expression of the survival motor neuron (SMN) protein. SMN has key functions in multiple RNA pathways, including the biogenesis of small nuclear ribonucleoproteins that are essential components of both major (U2-dependent) and minor (U12-dependent) spliceosomes. Here we investigated the specific contribution of U12 splicing dysfunction to SMA pathology through selective restoration of this RNA pathway in mouse models of varying phenotypic severity. We show that virus-mediated delivery of minor snRNA genes specifically improves select U12 splicing defects induced by SMN deficiency in cultured mammalian cells, as well as in the spinal cord and dorsal root ganglia of SMA mice without increasing SMN expression. This approach resulted in a moderate amelioration of several parameters of the disease phenotype in SMA mice, including survival, weight gain, and motor function. Importantly, minor snRNA gene delivery improved aberrant splicing of the U12 intron–containing gene Stasimon and rescued the severe loss of proprioceptive sensory synapses on SMA motor neurons, which are early signatures of motor circuit dysfunction in mouse models. Taken together, these findings establish the direct contribution of U12 splicing dysfunction to synaptic deafferentation and motor circuit pathology in SMA.

Authors

Erkan Y. Osman, Meaghan Van Alstyne, Pei-Fen Yen, Francesco Lotti, Zhihua Feng, Karen K.Y. Ling, Chien-Ping Ko, Livio Pellizzoni, Christian L. Lorson

×

Figure 4

Minor snRNA gene delivery does not increase SMN protein expression in SMA mice.

Options: View larger image (or click on image) Download as PowerPoint
Minor snRNA gene delivery does not increase SMN protein expression in SM...
Tissues for Western blot analysis were collected from brain, spinal cord, and gastrocnemius muscle. Western blot images showing SMN expression levels in tissues collected at P9 from heterozygous (unaffected) control mice as well as untreated and U11/U12- (A) or U11/U12/U4atac-treated (C) SMA mice. No significant changes in the SMN levels were observed in all tested tissues comparing samples from untreated and U11/U12- (B) or U11/U12/U4atac-treated (D) SMA mice. All SMA samples were predictably lower than unaffected samples. Actin was used as a loading control. Comparisons were analyzed by Student’s t test. *P < 0.05. Data expressed as mean ± SEM. n = 3 animals per group. Data in the scatter plots are presented as percentage of SMN normalized to control.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts